Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

NRXP, GOING FOR THE GOLD??? ———
NRx Pharmaceuticals Announces New Finding from ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19

https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-announces-new-finding-from-zyesami-aviptadil-phase-2b3-clinical-trial-demonstrating-clinically-significant-relief-from-respiratory-distress-in-critical-covid-19-301365091.html

NeuroRx Receives FDA Breakthrough Therapy Designation for NRX-101, First Oral Drug Targeting Suicidal Bipolar Depression

https://www.businesswire.com/news/home/20181113005407/en/NeuroRx-Receives-FDA-Breakthrough-Therapy-Designation-for-NRX-101-First-Oral-Drug-Targeting-Suicidal-Bipolar-Depression

The Real Value Of A Breakthrough Therapy Designation

Summary

——— Average approval time reduced by 2.5-3.5 years.
——— Breakthrough therapy designation usually increases valuation significantly.
——— Takeover offers typically increase with breakthrough therapy designations.
——— Takeover offers for a company with 2 breakthrough therapy designations increase significantly and quickly.
——— Evaluating high flyers and value companies.

https://seekingalpha.com/article/4314267-real-value-of-breakthrough-therapy-designation